Importantly, we define notable cancer vulnerabilities amongst synthetic lethal hits with EXO1 loss, such as deficiencies in BRCA1-A complex factors, Fanconi Anaemia pathway genes and the splicing factor and tumour suppressor ZRSR2. This evidence concerns the gene EXO1 and Fanconi anemia.